Ignite Creation Date:
2024-07-17 @ 10:58 AM
Last Modification Date:
2024-10-26 @ 3:32 PM
Study NCT ID:
NCT06470763
Status:
RECRUITING
Last Update Posted:
2024-07-03
First Post:
2024-06-14
Brief Title:
A Study Evaluating ANV600 Single Agent or in Combination with Pembrolizumab in Participants with Advanced Solid Tumors EXPAND-1
Sponsor:
Anaveon AG
Organization:
Anaveon AG
Study Overview
Official Title:
A First-in-human Open-label Multicenter Phase III Study to Evaluate the Safety and Anti-tumor Activity of ANV600 As Single Agent and in Combination with Pembrolizumab in Participants with Advanced Solid Tumors EXPAND-1
Status:
RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of study ANV600-001 is to characterize the safety tolerability pharmacokinetics PK pharmacodynamics immunogenicity and antitumor activity of ANV600 administered as a single agent or in combination with pembrolizumab in adult participants with advanced solid tumors
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| EXPAND-1 | OTHER | None | None |
| KEYNOTE-F78 | OTHER | None | None |
| MK-3475-F78 | OTHER | None | None |
| 2023-509633-39-00 | CTIS | None | None |